Core Viewpoint - Huatu Education has signed a cooperation agreement with Feishu to leverage AI technology for enhancing organizational efficiency and talent acquisition in vocational education [1][2]. Group 1: Partnership and AI Integration - The partnership aims to create an enterprise-level "native AI organization" that connects headquarters with over a thousand campuses and tens of thousands of employees [1]. - Huatu Education's CEO emphasized that the choice of Feishu represents a new organizational evolution model, enabling free information flow and structured knowledge accumulation [2]. Group 2: Talent Acquisition and Management - Huatu Education plans to utilize Feishu's AI capabilities to refine the talent discovery process, generating precise job descriptions and analyzing resumes to identify the best candidates [2]. - The concept of "management equals AI" is introduced, suggesting that AI should be integrated into the organization's core capabilities rather than merely added as a tool [2]. Group 3: Operational Efficiency and AI Applications - Huatu has activated 100% of its employees across 320 cities within two weeks, achieving a 93% activity rate, laying a solid foundation for AI implementation [3]. - Various AI applications have been deployed across nine operational areas, including strategic decision-making, human resources, and financial management, enhancing operational precision and efficiency [3]. Group 4: Employee Empowerment and Innovation - The launch of the "AI + Efficiency Pioneer" initiative encourages all employees to actively participate in the digital transformation and AI exploration [4]. - The founder of Huatu Education stated the importance of maintaining agility akin to a startup while leveraging advanced tools to empower every employee [4]. Group 5: Commitment to Quality and Innovation - The CEO of Feishu expressed alignment with Huatu Education's commitment to quality and innovation, highlighting the partnership's role in supporting Huatu's digital transformation and AI exploration [5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 XJ International Holdings Co., Ltd. 希教國際控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1765） 有關2026年框架協議的持續關連交易 重續持續關連交易 茲提述本公司日期為2018年7月24日的招股章程以及本公司日期為2021年2月11 日及2023年7月21日的公告。由於院校規模縮減，且為更有效運用物業及符合校 內服務的合規要求，董事會建議於2023年框架協議屆滿後，繼續進行其項下擬進 行的交易。由於需要額外時間就重續協議進行磋商，於2026年3月30日，希望教 育與特驅教育簽訂2026年框架協議，以重續相應的2023年框架協議，自2026財年 起至2028財年止為期三年。 上市規則涵義 於本公告日期，特驅教育為本公司主要股東四川特驅及成都五月花共同控股之公 司。因此，根據上市規則第14A章，特驅教育為本公司的關連人士。因此，2026 年框架協議項 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 XJ International Holdings Co., Ltd. 本公告乃由希教國際控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）自 願作出。 希教國際控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1765） 自願性公告 首席投資官變更 本公司董事（「董事」）會（「董事會」）謹此宣佈，自2026年3月13日起，譚澧先生（「譚 先生」）因工作安排調整，將不再擔任本公司首席投資官，惟將繼續留任本公司資本 市場總監。 董事會進一步宣佈，自2026年3月13日起，鄧怡先生（「鄧先生」）已獲委任為本公司 首席投資官，將主要負責管理本集團的現有投資組合及資本營運，優化本集團資本 結構，並執行本集團投資策略。 譚先生已確認，彼與董事會並無意見分歧，亦無有關彼辭任本公司首席投資官的事 宜須提請本公司股東或香港聯合交易所有限公司垂注。 董事會謹此對譚先生在任期間為本公司作出的貢獻表示衷心謝意 ...

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook for the sector's performance compared to the overall market [5][10]. Core Insights - The report highlights significant developments in the pharmaceutical sector, including a licensing agreement between China National Pharmaceutical Group (Sinopharm) and Sanofi for the JAK/ROCK inhibitor, and the approval of a new indication for Innovent Biologics' BTK inhibitor in China [1][2]. - Performance forecasts for companies such as Crystal Holding and He Yu indicate substantial revenue growth, with Crystal Holding expected to achieve at least 780 million RMB in revenue for 2025, representing a year-on-year increase of approximately 193% [6][7]. Summary by Sections 1. Overseas Pharmaceuticals - Sinopharm and Sanofi have entered into an exclusive licensing agreement for the global development, production, and commercialization of the JAK/ROCK inhibitor, with potential milestone payments totaling up to 1.395 billion USD [2][7]. - Innovent Biologics' BTK inhibitor, Jiepalit (Pirtobrutinib), has received NMPA approval for a new indication in adult patients with chronic lymphocytic leukemia (CLL) who have previously undergone systemic treatment [2][7]. - Roche's BTK inhibitor Fenebrutinib has successfully met primary endpoints in a Phase III trial for relapsing multiple sclerosis, potentially becoming the first effective oral treatment for both relapsing and primary progressive forms of the disease [3][8]. 2. Performance Updates - Crystal Holding anticipates a revenue of no less than 780 million RMB in 2025, with a net profit of at least 100 million RMB, marking a turnaround from losses [6][7]. - He Yu expects to achieve 612 million RMB in revenue for 2025, reflecting a 21% year-on-year growth, with net profit projected at 55 million RMB, a 95% increase [6][7]. 3. Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with active commercialization and business development opportunities, including companies like BeiGene, Innovent Biologics, and others [10]. - It also highlights the importance of monitoring clinical progress in key pipelines for companies transitioning towards innovation [10].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 XJ International Holdings Co., Ltd. 希教國際控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1765） (1)聯席公司秘書、授權代表及法律程序文件代理人變更； (2)豁免嚴格遵守上市規則第3.28條及第8.17條； 及 – 1 – 董事會欣然宣佈，在譚先生及陳女士辭任後，劉曉陽女士（「劉女士」）及王嘉慈女士 （「王女士」）已獲委任為聯席公司秘書，自2026年3月6日起生效。王女士亦已獲委任 為授權代表及法律程序文件代理人，自2026年3月6日起生效。 劉女士及王女士的履歷詳情載列如下： 劉女士 劉女士於2011年11月加入本公司，現為本公司投資者關係總監及董事會執行人員。 彼曾於四川中聯會計師事務所有限公司擔任審計經理五年。 劉女士畢業於西南財經大學，獲會計學碩士學位。 (3)香港主要營業地點地址變更 聯席公司秘書、授權代表及法律程序文件代理人變更 希教國際 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 公司名稱: 希教國際控股有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01765 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.00001 | USD | | 100,000 | | 增加 / 減少 (-) | | | 10,000,000,000 | | | | USD | | 100,000 | | 本月底結存 | | | 20,000,000,000 | USD | | 0.00001 | USD | | 200,000 | ...

Group 1: Industry Investment Rating - The investment rating for the overseas social services industry is positive, with a focus on the record-high visitor numbers during the Macau Spring Festival [6]. Group 2: Core Insights - The total number of inbound visitors to Macau during the Spring Festival reached 1.554 million, with an average daily visitor count of 173,000, marking a year-on-year increase of 5.5% [6][1]. - Among the inbound visitors, mainland tourists averaged 134,000 per day, reflecting a 7% year-on-year growth, while international visitors averaged nearly 7,900 per day, up by 8% [6][1]. - The hotel occupancy rate during the Spring Festival was 95.6%, with the highest rate of 99.2% recorded on the fourth day of the festival [6][1]. Group 3: Summary by Relevant Sections Overseas Pharmaceuticals - The report highlights significant developments in the pharmaceutical sector, including the announcement of clinical trial results for B7-H3 ADC by Yingensheng and the completion of Phase II trials for UBT251 by Lianbang Pharmaceutical [3][10]. - In 2025, BeiGene reported revenues of $5.343 billion, a 40% increase year-on-year, while adjusted net profits reached $917 million, marking a return to profitability [9][21]. - The report also notes that the average weight loss in the UBT251 trial was as high as 19.7% after 24 weeks, compared to a 2.0% loss in the placebo group [11][10]. Overseas Education - The vocational education sector is experiencing an upswing, with promising enrollment data, particularly for China Oriental Education [5][17]. - The education index saw a decline of 4.9% in the recent week, underperforming the Hang Seng National Enterprises Index by 2.1 percentage points [15]. - The report recommends focusing on China Oriental Education, which is expected to see accelerated enrollment growth due to its strategic adjustments in response to market demands [17][15].

Group 1 - Mr. Wang Shunhong has been appointed as an independent non-executive director, effective from February 27, 2026 [1] - Ms. Wang Xiu has been re-designated from executive director to non-executive director due to personal reasons, effective from February 27, 2026 [1] - Mr. Zhang Bing and Mr. Wang Xiaowu have been re-designated from non-executive directors to executive directors, effective from February 27, 2026 [1] Group 2 - Mr. Wang has been appointed as a member of the Board Audit Committee and the Board Nomination and Remuneration Committee, effective from February 27, 2026 [1] - Mr. Wang Xiaowu will no longer serve as a member of the Audit Committee [1] - Mr. Xu Changjun has been appointed as a member of the Board Strategy and Development Committee [1] - Mr. Wang Huiwu will no longer serve as a member of the Nomination and Remuneration Committee [1] - Mr. Zhang has been appointed as a member of the Nomination and Remuneration Committee [1] - Ms. Wang will no longer serve as a member of the Strategy and Development Committee and has been appointed as a member of the Audit Committee [1]

Group 1 - Mr. Wang Shunhong has been appointed as an independent non-executive director, effective from February 27, 2026 [1] - Ms. Wang Xiu has been re-designated from executive director to non-executive director due to personal matters, effective from February 27, 2026 [1] - Mr. Zhang Bing and Mr. Wang Xiaowu have been re-designated from non-executive directors to executive directors, effective from February 27, 2026 [1] Group 2 - Mr. Wang has been appointed as a member of the Board Audit Committee and the Board Nomination and Remuneration Committee, effective from February 27, 2026 [1] - Mr. Wang Xiaowu will no longer serve as a member of the Audit Committee, effective from February 27, 2026 [1] - Mr. Xu Changjun has been appointed as a member of the Board Strategy and Development Committee, effective from February 27, 2026 [1] - Mr. Wang Huiwu will no longer serve as a member of the Nomination and Remuneration Committee, effective from February 27, 2026 [1] - Mr. Zhang has been appointed as a member of the Nomination and Remuneration Committee, effective from February 27, 2026 [1] - Ms. Wang will no longer serve as a member of the Strategy and Development Committee and has been appointed as a member of the Audit Committee, effective from February 27, 2026 [1]

Group 1 - The board of directors of Xue Education International Holdings (01765.HK) announced the appointment of Wang Shunhong as an independent non-executive director, effective from February 27, 2026 [1] - Due to personal matters, Wang Xiu has been reassigned from executive director to non-executive director, effective from February 27, 2026 [1] - Zhang Bing and Wang Xiaowu have been reassigned from non-executive directors to executive directors due to work adjustments, effective from February 27, 2026 [1]